updating data for batch codes

docs/SymptomsCausedByDrugs/data/ProportionalReportingRatios/vaccines/695.json

@@ -1 +1 @@
-{"acute hepatitis b": 98.26, "acute myeloid leukaemia": 3.83, "acute respiratory distress syndrome": 4.47, "agranulocytosis": 23.74, "anaemia": 2.85, "bone marrow failure": 15.85, "cardiac failure": 2.43, "cardiomyopathy": 4.46, "cytomegalovirus infection": 4.63, "cytopenia": 10.74, "dermatitis exfoliative generalised": 6.48, "diffuse large b-cell lymphoma recurrent": 51.53, "disease progression": 3.86, "disease recurrence": 2.66, "ejection fraction decreased": 4.47, "febrile bone marrow aplasia": 57.66, "febrile neutropenia": 24.0, "full blood count decreased": 5.51, "general physical health deterioration": 2.08, "granulocyte count decreased": 29.95, "granulocytopenia": 10.92, "haemoglobin decreased": 2.26, "hepatic cytolysis": 4.1, "hepatic failure": 3.22, "hepatitis b": 15.97, "hepatitis b reactivation": 76.31, "hypogammaglobulinaemia": 23.84, "infection": 3.84, "infusion related reaction": 7.04, "intentional product use issue": 5.62, "interstitial lung disease": 8.11, "leukopenia": 9.9, "lung disorder": 4.01, "lung infiltration": 5.67, "lymphoma": 4.23, "lymphopenia": 7.14, "mucosal inflammation": 6.08, "multiple organ dysfunction syndrome": 2.91, "myelosuppression": 39.63, "neutropenia": 11.77, "neutrophil count decreased": 19.04, "off label use": 2.46, "pancytopenia": 10.85, "platelet count decreased": 5.16, "pneumocystis jirovecii pneumonia": 57.18, "pneumonia": 3.47, "pneumonitis": 6.41, "polyneuropathy": 5.75, "progressive multifocal leukoencephalopathy": 109.98, "pulmonary fibrosis": 5.78, "sepsis": 3.73, "septic shock": 6.59, "serum sickness": 14.19, "splenomegaly": 4.04, "thrombocytopenia": 4.62, "tumour lysis syndrome": 6.85, "white blood cell count decreased": 17.23}
+{"acne": 5.07, "aspartate aminotransferase increased": 2.37, "blindness": 2.04, "blood creatine phosphokinase increased": 9.23, "blood lactate dehydrogenase increased": 5.2, "blood sodium decreased": 2.38, "brain neoplasm": 12.01, "brain oedema": 2.95, "c-reactive protein increased": 3.93, "cardiomyopathy": 2.91, "cardiotoxicity": 5.33, "central nervous system lesion": 9.74, "cholestasis": 7.3, "colon cancer": 2.75, "concomitant disease aggravated": 2.53, "death": 5.32, "dehydration": 2.8, "dermatitis acneiform": 21.41, "disease progression": 2.74, "disseminated intravascular coagulation": 2.65, "drug reaction with eosinophilia and systemic symptoms": 2.15, "dry skin": 3.74, "dysphagia": 2.47, "ejection fraction decreased": 20.61, "electrolyte imbalance": 3.12, "erythema nodosum": 16.74, "gamma-glutamyltransferase increased": 2.07, "general physical health deterioration": 2.31, "haemophagocytic lymphohistiocytosis": 9.04, "hepatic cytolysis": 7.35, "hepatic enzyme increased": 2.45, "hepatic function abnormal": 2.47, "hepatitis": 2.69, "hospitalisation": 2.7, "hyperkeratosis": 5.27, "hyperpyrexia": 2.18, "hyperthermia": 5.69, "hyponatraemia": 2.85, "intestinal perforation": 3.55, "lipase increased": 3.2, "liver disorder": 2.97, "liver function test increased": 3.88, "lung adenocarcinoma": 12.0, "lung neoplasm malignant": 9.76, "lymphocyte count decreased": 2.71, "lymphoedema": 2.71, "malignant melanoma": 59.27, "malignant melanoma stage iii": 48.55, "malignant melanoma stage iv": 166.05, "malignant neoplasm progression": 15.39, "melanoma recurrent": 103.05, "metastases to bone": 7.74, "metastases to central nervous system": 58.31, "metastases to liver": 7.9, "metastases to lung": 13.11, "metastases to lymph nodes": 15.62, "metastases to meninges": 18.92, "metastases to peritoneum": 8.36, "metastases to skin": 27.71, "metastasis": 19.03, "metastatic malignant melanoma": 162.3, "neoplasm": 5.23, "non-small cell lung cancer": 34.12, "panniculitis": 35.99, "papilloedema": 4.62, "paronychia": 5.24, "pneumonitis": 2.85, "product storage error": 2.45, "product use in unapproved indication": 9.9, "pulmonary mass": 2.8, "pyrexia": 2.08, "rash": 2.23, "rash maculo-papular": 3.86, "rash pustular": 4.21, "recurrent cancer": 10.56, "retinal detachment": 11.38, "retinopathy": 4.84, "rhabdomyolysis": 8.8, "sarcoidosis": 5.0, "second primary malignancy": 10.15, "serous retinal detachment": 26.38, "skin lesion": 3.1, "skin toxicity": 5.71, "soft tissue sarcoma": 37.1, "therapy partial responder": 2.32, "thyroid cancer": 5.45, "toxic skin eruption": 2.27, "tubulointerstitial nephritis": 2.78, "uveitis": 20.57, "visual impairment": 3.05, "vitreous floaters": 2.48}